Pembrolizumab (Keytruda) for the first-line treatment of advanced renal cell cancer with a poor prognosis
In 2020, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into the advantages and disadvantages of pembrolizumab in combination with axitinib compared to the standard treatments for advanced renal cell carcinoma with a poor in adults who have not yet had any treatment.
The manufacturer provided one study for this assessment. It was possible to analyze the data of 108 patients from this study. 56 of them were given pembrolizumab and axitinib, and 52 received sunitinib.
This is what was found: